Europe Oncology Biosimilars Market: Market Estimation, Dynamics, Country Share, Trends, Competitor Analysis 2017-2021 and Forecast 2022 to 2028

$ PRICE - $ 2,000.00$ 6,900.00

Europe Oncology Biosimilars Market: By Drug Class (Monoclonal Antibodies (mAb), Granulocyte Colony Stimulating Factors (G-CSF) and Hematopoietic Agents), By Cancer Type (Blood Cancer, Breast Cancer and Others), By Indication (Malignant Lymphoma or Multiple Myeloma, HER2 Positive Metastatic Breast Cancer (MBC), Neutropenia, and Non-Hodgkin’s Lymphoma (NHL)) By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and Country

 

 

$ PRICE - $ 2,000.00$ 6,900.00
Clear selection
Clear
$ PRICE - $ 2,000.00$ 6,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Category:

Report

Description

Europe Oncology Biosimilars market size is valued at USD 6,953.2 million in 2021 and is expected to grow at a CAGR of 19.2% during the forecast period 2022 to 2028. The European market provides a detailed overview of the Europe Oncology Biosimilars market, and that can be segmented by drug class, by cancer type, and by indication. By drug class, The Europe Oncology Biosimilars market has been segmented into Monoclonal Antibodies (mAb), Granulocyte Colony Stimulating Factors (G-CSF) and Hematopoietic Agents. The Monoclonal Antibodies (mAb) segment is likely to be the largest and fastest-growing segment in terms of drug class. Monoclonal antibodies and Insulin are seen to be the foremost segments regarding the growth rate during the forecast period because of extensive applications of monoclonal antibodies in the treatment of autoimmune disorders, cancer, and osteoporosis, and growing incidents of insulin dependent diabetes worldwide and growing demand for lucrative treatment options. Based on the Cancer type, the Europe Oncology Biosimilars market is segmented into Blood Cancer, Breast Cancer and Others Among these, the Breast Cancer segment is expected to have a significant growing market during the forecast period 2022-2028. The accessibility of biosimilars in the field of oncology has dropped prices and made cancer treatment more accessible and affordable. Also, due to the increasing prevalence of cancer, healthcare systems around the world are focusing on dropping the burden of cancer by accepting cost effective treatment choices. Based on the Indication, the Europe Oncology Biosimilars market is segmented into Malignant Lymphoma or Multiple Myeloma, HER2 Positive Metastatic Breast Cancer (MBC), Neutropenia, and Non-Hodgkin’s Lymphoma (NHL). The Metastatic Breast Cancer (MBC), segment accounts for the significant share in 2021. Based on the distribution channel, the Europe Oncology Biosimilars market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. The Hospital Pharmacies segment accounts for the significant share in 2021.

Key Developments:

In April 2021, Mylan (now Viatris) launched Abevmy a biosimilar for oncology

In March 2021, mAbxience Research launched Alymsys, a biosimilar for various types of cancer

Europe Oncology Biosimilars Market

MARKET SUMMARY
-
19.2%
  • Study Period– 2022 – 2028
  • Base Year– 2021
  • CAGR– 19.2%

Europe Oncology Biosimilars Market

  • The europe oncology biosimilars market report gives comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • The europe oncology biosimilars market is segmented based on drug class, cancer type, indication, distribution channel and country
Key Players
  • Sandoz International GmbH
  • Amgen Inc.
  • Celltrion Healthcare Co., Ltd.
  • Samsung Bioepis
Europe Oncology Biosimilars Market Drivers

Europe Oncology Biosimilars market is chiefly driven by the cost-effectiveness and increasing demand for biosimilars


Germany Got Significant Share

Europe Oncology Biosimilars Market

Germany, Italy, UK, France, Spain, Russia, and Poland market is expected to witness the highest market share during the forecast period.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Features of the Report

  • The Europe oncology biosimilars market provides granular level information about the market size, regional market share, historic market (2017-2021) and forecast (2022-2028)
  • The Europe oncology biosimilars market covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The Europe oncology biosimilars market outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The Europe oncology biosimilars market tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The Europe oncology biosimilars market provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Europe Oncology Biosimilars Market Segmentation


Location

GEOGRAPHY

Frequently Asked Questions

The europe oncology biosimilars market is projected to expand at a CAGR of 19.2% during the forecast period

Sandoz International GmbH (Germany), Amgen Inc. (U.S.), Celltrion Healthcare Co., Ltd. (South Korea), Samsung Bioepis (South Korea)


Report

Table Of Content

Table of Content

  1. Executive Summary
  2. Europe Oncology Biosimilars Market Introduction
    • Europe Oncology Biosimilars Market – Taxonomy
    • Europe Oncology Biosimilars Market –Definitions
      • Drug Class
  1. Europe Oncology Biosimilars Market Dynamics
    • Drivers
    • Restraints
    • Opportunities/Unmet Needs of the Market
    • Trends
    • Colorectal Cancer Biosimilar Landscape
    • Colorectal Cancer Treatment Landscape
    • Barriers to the Uptake of Bevacizumab Biosimilars
    • Breast Cancer Biosimilar Landscape
    • Barriers to the Uptake of Trastuzumab Biosimilars
    • NHL and CLL Biosimilar Landscape
    • NHL and CLL Treatment Landscape
    • Barriers to the Uptake of Rituximab Biosimilars
    • Patent Expiration and sales of Major Oncology Biologics
    • Biosimilar Landscape for Supportive care in Oncology
    • EU5 Biosimilars Market Potential
    • EMA Approved Oncology Biosimilars
    • Biosimilars Pricing & Reimbursement in Europe
    • Europe Oncology Biosimilars Market Dynamic Factors – Impact Analysis
  2. Europe Oncology Biosimilars Market Analysis, 2016-2017 and Forecast, 2018 – 2024
    • Market Analysis, 2016-2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
    • Year-over-Year (Y-o-Y) Growth Analysis (%)
    • Market Opportunity Analysis
  3. Europe Oncology Biosimilars Market, By Drug Class, 2016-2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
    • Monoclonal Antibodies
      • Market Analysis, 2016-2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Granulocyte Colony Stimulating Factor
      • Market Analysis, 2016-2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Hematopoietic Agents
      • Market Analysis, 2016-2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Europe Oncology Biosimilars Market Forecast, By Cancer Type, 2016-2017 and Forecast, 2017 – 2024
    • Blood Cancer
      • Market Analysis, 2016-2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Breast Cancer
      • Market Analysis, 2016-2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Others
      • Market Analysis, 2016-2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Europe Oncology Biosimilars Market Forecast, By Distribution Channel, 2016-2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
    • Hospital Pharmacies
      • Market Analysis, 2016-2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Retail Pharmacies
      • Market Analysis, 2016-2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Online Pharmacies
      • Market Analysis, 2016-2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Europe Oncology Biosimilars Market Forecast, By Region, 2016-2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
    • Germany
      • Market Analysis, 2016-2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • France
      • Market Analysis, 2016-2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • UK
      • Market Analysis, 2016-2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Italy
      • Market Analysis, 2016-2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Spain
      • Market Analysis, 2016-2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Europe Oncology Biosimilars Market – Opportunity Analysis Index, By Drug Class, By Cancer Type, By Distribution Channel, and Region, 2018 – 2024
  2. Germany Oncology Biosimilars Market Analysis, 2016-2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
    • Drug Class Analysis 2016-2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Monoclonal antibodies
      • Granulocyte Colony Stimulating Factor
      • Hematopoietic Agents
    • Cancer Type Analysis 2016-2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Blood Cancer
      • Breast Cancer
      • Others
    • Distribution Channel Analysis 2016-2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Germany Oncology Biosimilars Market – Opportunity Analysis Index, By Drug Class, By Cancer Type, and By Distribution Channel, 2018 – 2024
    • Germany Oncology Biosimilars Market Dynamics – Trends
  3. France Oncology Biosimilars Market Analysis, 2016-2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
    • Drug Class Analysis 2016-2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Monoclonal antibodies
      • Granulocyte Colony Stimulating Factor
      • Hematopoietic Agents
    • Cancer Type Analysis 2016-2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Blood Cancer
      • Breast Cancer
      • Others
    • Distribution Channel Analysis 2016-2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • France Oncology Biosimilars Market – Opportunity Analysis Index, By Drug Class, By Cancer Type, and By Distribution Channel, 2018 – 2024
    • France Oncology Biosimilars Market Dynamics – Trends
  4. UK Oncology Biosimilars Market Analysis, 2016-2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
    • Drug Class Analysis 2016-2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Monoclonal antibodies
      • Granulocyte Colony Stimulating Factor
      • Hematopoietic Agents
    • Cancer Type Analysis 2016-2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Blood Cancer
      • Breast Cancer
      • Others
    • Distribution Channel Analysis 2016-2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • UK Oncology Biosimilars Market – Opportunity Analysis Index, By Drug Class, By Cancer Type, and By Distribution Channel, 2018 – 2024
    • UK Oncology Biosimilars Market Dynamics – Trends
  5. Italy Oncology Biosimilars Market Analysis, 2016-2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
    • Drug Class Analysis 2016-2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Monoclonal antibodies
      • Granulocyte Colony Stimulating Factor
      • Hematopoietic Agents
    • Cancer Type Analysis 2016-2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Blood Cancer
      • Breast Cancer
      • Others
    • Distribution Channel Analysis 2016-2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Italy Oncology Biosimilars Market – Opportunity Analysis Index, By Drug Class, By Cancer Type, and By Distribution Channel, 2018 – 2024
  6. Spain Oncology Biosimilars Market Analysis, 2016-2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
    • Drug Class Analysis 2016-2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Monoclonal antibodies
      • Granulocyte Colony Stimulating Factor
      • Hematopoietic Agents
    • Cancer Type Analysis 2016-2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Blood Cancer
      • Breast Cancer
      • Others
    • Distribution Channel Analysis 2016-2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Spain Oncology Biosimilars Market – Opportunity Analysis Index, By Drug Class, By Cancer Type, and By Distribution Channel, 2018 – 2024
    • Spain Oncology Biosimilars Market Dynamics – Trends
  7. Competition Landscape
    • Strategic Dashboard of Top Market Players
    • Company Profiles (Introduction, Financial Analysis, Product Offerings, Key Developments, Strategies, and SWOT Analysis)
      • Amgen
      • Sandoz International GmbH (Novartis AG)
      • Celltrion Healthcare
      • Samsung Bioepis UK Limited (SBUK)
  1. Research Methodology
  2. Key Assumptions and Acronyms


Report

Company Profile

  • Sandoz International GmbH (Germany)
  • Amgen Inc. (U.S.)
  • Celltrion Healthcare Co., Ltd. (South Korea)
  • Samsung Bioepis (South Korea)

Description

Europe Oncology Biosimilars market size is valued at USD 6,953.2 million in 2021 and is expected to grow at a CAGR of 19.2% during the forecast period 2022 to 2028. The European market provides a detailed overview of the Europe Oncology Biosimilars market, and that can be segmented by drug class, by cancer type, and by indication. By drug class, The Europe Oncology Biosimilars market has been segmented into Monoclonal Antibodies (mAb), Granulocyte Colony Stimulating Factors (G-CSF) and Hematopoietic Agents. The Monoclonal Antibodies (mAb) segment is likely to be the largest and fastest-growing segment in terms of drug class. Monoclonal antibodies and Insulin are seen to be the foremost segments regarding the growth rate during the forecast period because of extensive applications of monoclonal antibodies in the treatment of autoimmune disorders, cancer, and osteoporosis, and growing incidents of insulin dependent diabetes worldwide and growing demand for lucrative treatment options. Based on the Cancer type, the Europe Oncology Biosimilars market is segmented into Blood Cancer, Breast Cancer and Others Among these, the Breast Cancer segment is expected to have a significant growing market during the forecast period 2022-2028. The accessibility of biosimilars in the field of oncology has dropped prices and made cancer treatment more accessible and affordable. Also, due to the increasing prevalence of cancer, healthcare systems around the world are focusing on dropping the burden of cancer by accepting cost effective treatment choices. Based on the Indication, the Europe Oncology Biosimilars market is segmented into Malignant Lymphoma or Multiple Myeloma, HER2 Positive Metastatic Breast Cancer (MBC), Neutropenia, and Non-Hodgkin’s Lymphoma (NHL). The Metastatic Breast Cancer (MBC), segment accounts for the significant share in 2021. Based on the distribution channel, the Europe Oncology Biosimilars market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. The Hospital Pharmacies segment accounts for the significant share in 2021.

Key Developments:

In April 2021, Mylan (now Viatris) launched Abevmy a biosimilar for oncology

In March 2021, mAbxience Research launched Alymsys, a biosimilar for various types of cancer

ASIA PACIFIC OFFICE

Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad - 500072

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX